ACOG Guideline Revisions Boost Myriad’s BRCA Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.
You may also be interested in...
Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.
Myriad Weighs Strategic Alternatives
Management is undertaking a strategic review to evaluate alternatives for running its diagnostics and pharmaceuticals business separately.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf